medical imaging

Government agencies are flooded with a tidal wave of data. But a number of healthcare agencies are facing particularly challenging obstacles to achieving their missions in a digital and data interoperable world. This is particularly true for regulatory healthcare agencies such as the Food and Drug Administration (FDA).

As outlined in the agency’s “FDA Science and Mission at Risk” report dating back to 2007, the FDA anticipated many of these challenges. The report detailed new data sources coming from new digital sciences including the use of molecular data for medicine (e.g., genomics, proteomics, and pan-omics), wireless healthcare, nanotechnology, medical imaging, telemedicine platforms, electronic health records and more. Keep reading →